Entries by arcticnovartis

Novartis Kisqali® reduces risk of recurrence in younger patients with early breast cancer in NATALEE subgroup analysis

Novartis Kisqali® reduces risk of recurrence in younger patients with early breast cancer in NATALEE subgroup analysis
arcticnovartis
Sun, 06/01/2025 – 15:04

Read more about Novartis Kisqali® reduces risk of recurrence in younger patients with ear…

Novartis announces commencement of tender offer to acquire Regulus Therapeutics

Novartis announces commencement of tender offer to acquire Regulus Therapeutics
arcticnovartis
Tue, 05/27/2025 – 14:04

Read more about Novartis announces commencement of tender offer to acquire Regulus Therapeutics

Basel, May 27, 2…

New Novartis data at ASCO and EHA showcase momentum of pioneering portfolio with promising pipeline

New Novartis data at ASCO and EHA showcase momentum of pioneering portfolio with promising pipeline
arcticnovartis
Thu, 05/15/2025 – 15:04

Read more about New Novartis data at ASCO and EHA showcase momentum of pioneering portfolio with promising …

Novartis erzielt im zweiten Quartal weiterhin kräftige Umsatzsteigerungen und erhöht die Kerngewinnmarge; Gewinnprognose für das Geschäftsjahr 2024 angehoben

Novartis erzielt im zweiten Quartal weiterhin kräftige Umsatzsteigerungen und erhöht die Kerngewinnmarge; Gewinnprognose für das Geschäftsjahr 2024 angehoben
arcticnovartis
Mon, 05/05/2025 – 13:04

Read more about Novartis erzielt im zweiten Quarta…

Novartis Scemblix® Phase III data first to show superior efficacy with a favorable safety and tolerability profile vs. standard-of-care TKIs in adults with newly diagnosed CML

Novartis Scemblix® Phase III data first to show superior efficacy with a favorable safety and tolerability profile vs. standard-of-care TKIs in adults with newly diagnosed CML
arcticnovartis
Mon, 05/05/2025 – 13:04

Read more about Novartis Scembl…

Latest analysis of Novartis NATALEE study shows Kisqali® reduces risk of cancer recurrence for early breast cancer patients with high-risk node-negative disease

Latest analysis of Novartis NATALEE study shows Kisqali® reduces risk of cancer recurrence for early breast cancer patients with high-risk node-negative disease
arcticnovartis
Mon, 05/05/2025 – 13:04

Read more about Latest analysis of No…

Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company’s IgA nephropathy (IgAN) portfolio

Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company’s IgA nephropathy (IgAN) portfolio
arcticnovartis
Mon, 05/05/2025 – 13:04

Read more about Novartis atrasentan Phase III data show clinica…

Novartis Phase III data confirm sustained efficacy and long-term safety of oral remibrutinib in chronic spontaneous urticaria

Novartis Phase III data confirm sustained efficacy and long-term safety of oral remibrutinib in chronic spontaneous urticaria
arcticnovartis
Mon, 05/05/2025 – 13:04

Read more about Novartis Phase III data confirm sustained efficacy and long-term s…

Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo

Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo
arcticnovartis
Mon, 05/05/2025 – 13:04…

Novartis meets all tender offer conditions to acquire MorphoSys AG for EUR 68 per share in cash

Novartis meets all tender offer conditions to acquire MorphoSys AG for EUR 68 per share in cash
arcticnovartis
Mon, 05/05/2025 – 13:04

Read more about Novartis meets all tender offer conditions to acquire MorphoSys AG for EUR 68 per share in cash